How to manage and improve appetite in patients with impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Managing and Improving Appetite in Patients with Impaired Renal Function

Optimize dialysis adequacy first by ensuring weekly Kt/Vurea ≥2.0 for hemodialysis patients and appropriate creatinine clearance targets for peritoneal dialysis patients, as inadequate dialysis directly causes uremic anorexia through toxin accumulation. 1, 2

Address Underlying Reversible Causes

Before implementing nutritional interventions, systematically eliminate factors suppressing appetite:

Optimize Dialysis Adequacy

  • Ensure weekly Kt/Vurea ≥2.0 for hemodialysis patients, as inadequate dialysis (Kt/Vurea <2.0) directly causes uremic symptoms including nausea, vomiting, and anorexia 1, 2
  • For peritoneal dialysis patients, target creatinine clearance ≥60 L/week/1.73 m² for high/high-average transporters or ≥50 L/week/1.73 m² for low/low-average transporters 1
  • Increasing dialysis dose may improve appetite by reducing uremic toxins, though evidence for improved nutritional markers from dose increases alone remains limited 1

Treat Metabolic Derangements

  • Correct metabolic acidosis, which contributes to appetite suppression and protein catabolism 3, 2
  • Address hormonal deficiencies that may impair appetite 3
  • Evaluate and treat insulin resistance, which disrupts normal metabolic signaling 2

Manage Inflammation

  • Recognize that chronic inflammation produces proinflammatory cytokines (TNF-α, IL-6) directly associated with diminished appetite 1, 2, 4, 5
  • Anti-inflammatory interventions represent emerging therapies, though specific protocols require further validation 3, 6
  • Poor appetite is associated with elevated C-reactive protein >10 mg/L (odds ratio 2.39) 4

Review Medications and Comorbidities

  • Eliminate or modify medications interfering with appetite 3
  • Treat superimposed acute or chronic diseases, psychiatric illnesses, and gastroparesis 3, 2
  • Address mechanical impairments (lack of dentures) and cultural food preferences 3

Nutritional Support Strategies

First-Line: Dietary Counseling and Oral Nutritional Supplements (ONS)

  • Provide intensive nutritional counseling by an experienced renal dietitian as the initial intervention 3, 7
  • Offer ONS when oral intake fails to meet ≥70% of daily macronutrient requirements 3, 1, 7
  • ONS can add 10-12 kcal/kg and 0.3-0.5 g protein/kg daily when provided twice daily 3
  • Administer ONS 2-3 hours after usual meals to avoid suppressing regular food intake 7
  • Late evening ONS reduces overnight catabolism without affecting daytime food consumption 7
  • Intradialytic delivery of ONS during hemodialysis sessions improves compliance 7
  • ONS combined with dietary counseling should be attempted before considering intradialytic parenteral nutrition 1

Second-Line: Enteral Nutrition

  • If oral intake including ONS remains inadequate after counseling, consider tube feeding if medically appropriate 3, 7
  • Enteral nutrition is indicated when oral intake cannot meet at least 70% of daily requirements 3
  • Tube feeding has been used successfully in infants and children receiving maintenance dialysis 3

Third-Line: Intradialytic Parenteral Nutrition (IDPN)

  • Reserve IDPN for malnourished hemodialysis patients who fail to respond to or cannot tolerate ONS or enteral nutrition 3, 1, 7
  • IDPN provides nutrients during the 3-4 hour hemodialysis session three times weekly 3, 1
  • Multiple RCTs showed nutritional improvements with IDPN in patients with overt protein-energy wasting 3
  • IDPN is non-superior to ONS but represents a reasonable option when first-line treatments fail 3

Fourth-Line: Total Parenteral Nutrition

  • Consider daily total or partial parenteral nutrition if the combination of oral intake and IDPN does not meet protein and energy requirements 3

Nutritional Targets

Protein Requirements

  • Target protein intake of 1.2 g/kg/day for stable hemodialysis patients 7
  • Do not restrict protein intake to <0.8 g/kg/day in dialysis patients, as malnutrition risk exceeds theoretical benefits of protein restriction 1
  • At least 50% of protein should come from high biological value sources (animal proteins, whey, egg albumin) 7
  • In acute sepsis or critical illness, increase protein to 1.2-1.5 g/kg/day 7

Energy Requirements

  • Target 30-35 kcal/kg/day for patients ≥60 years old 7
  • Adequate energy intake prevents protein catabolism for energy 7

Monitoring Parameters

Nutritional Markers

  • Monitor normalized protein nitrogen appearance (nPNA) targeting ≥0.9-1.1 g/kg/day, as values below this suggest inadequate protein intake 1, 7
  • Assess serum albumin every 1-4 months, maintaining above the lower limit of laboratory normal range 1, 7
  • Monitor for >10% body weight loss over 6 months and maintain BMI >20 kg/m² 7
  • Use subjective global assessment (SGA) and edema-free body weight trends 1

Metabolic Monitoring

  • Monitor plasma electrolytes and phosphorus closely when initiating nutritional support to prevent refeeding syndrome 7
  • The dialysis regimen should be regularly monitored and modified to treat any intensification of uremia caused by increased protein intake 3, 7
  • Monitor phosphorus and potassium content carefully when increasing protein intake, as protein-rich foods are major sources of these minerals 7

Emerging Pharmacologic Appetite Stimulants

Considerations for Appetite Stimulants

  • Appetite stimulants represent emerging therapies for protein-energy wasting 3
  • Megestrol acetate carries significant risks including new-onset diabetes, Cushing's syndrome, and adrenal insufficiency with chronic use 8
  • Laboratory evaluation for adrenal insufficiency and consideration of stress-dose glucocorticoids are strongly recommended in patients receiving chronic megestrol acetate 8
  • Mirtazapine causes appetite increase in 17% of patients and weight gain ≥7% in 7.5% of patients, but also causes somnolence in 54% of patients 9
  • Mirtazapine carries risks of QTc prolongation, serotonin syndrome, and DRESS syndrome 9

Anabolic Strategies

  • Anabolic steroids, growth hormone, and exercise in combination with nutritional supplementation have shown improvements in protein stores 3
  • These represent potential additional approaches for treating protein-energy wasting 3

Critical Pitfalls to Avoid

  • Do not delay nutritional intervention: inadequate intake for even days to 2 weeks can worsen outcomes depending on baseline nutritional status 7
  • Avoid overfeeding, particularly glucose administration exceeding 7 mg/kg/min, which increases hepatic complication risk 7
  • Do not use IDPN as first-line therapy: ONS combined with dietary counseling should be attempted first 3, 1
  • Recognize that hospitalized dialysis patients often ingest only 66% of protein and 50% of energy requirements even when needs increase during acute illness 3, 2
  • Poor appetite is associated with 4-fold increased mortality risk (hazard ratio 4.74), making aggressive intervention essential 5

References

Guideline

Appetite Stimulation in Dialysis Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Causes of Decreased Appetite in Renal Failure Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Nutrition, inflammation and chronic kidney disease.

Current opinion in nephrology and hypertension, 2008

Guideline

Nutritional Support for Patients with End-Stage Renal Disease on Hemodialysis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.